pioglitazone

Pioglitazone (U 72107) is an insulin sensitizing agent and thiazolidinedione indicated for the treatment of type 2 diabetes, and has been linked to rare instances of acute liver injury.

Pioglitazone hydrochloride (AD 4833) is the hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.

Pioglitazone D4 is a deuterium labeled Pioglitazone. Pioglitazone is a agonist of PPARγ .

Pioglitazone potassium (U 72107) is an orally active, selective agonist of peroxisome proliferator-activated receptor gamma (PPARγ), exhibiting high-affinity binding to the ligand-binding domain of PPARγ with EC50 values of 0.93 μM for human and 0.99 μM for mouse PPARγ. It has applications in diabetes research [2] [3] [4].

(R)-Pioglitazone ((+)-pioglitazone), the R enantiomer of Pioglitazone, serves as a selective and orally active peroxisome proliferator-activated receptor (PPARγ) agonist. It exhibits high-affinity binding to the PPARγ ligand-binding domain and is utilized in research related to Alzheimers disease.

Hydroxy Pioglitazone M-IV-d4 is a deuterated compound of Hydroxy Pioglitazone M-IV.

Keto Pioglitazone-d4 is a deuterated compound of Keto Pioglitazone. Keto Pioglitazone has a CAS number of 146062-45-5. Ketopioglitazone is an active metabolite of pioglitazone.

Ketopioglitazone is an active metabolite of pioglitazone.

Leriglitazone, a metabolite of pioglitazone, binds to the PPARγ C-terminal ligand-binding domain (Ki: 1.2 μM) and induces transcriptional efficacy of the PPARγ (EC50: 680 nM). Leriglitazone PioOH is a PPARγ agonist, stabilizes the PPARγ activation functio

DRX-065 is a stabilized and deuterated R-enantiomer of pioglitazone. DRX-065 has pharmacological properties desirable for the treatment of NASH (mitochondrial function modulation, non-steroidal anti-inflammatory effects, and glucose lowering effects) with

Leriglitazone (Hydroxypioglitazone) hydrochloride, a pioglitazone metabolite, acts as a PPARγ agonist, effectively stabilizing the PPARγ activation function-2 (AF-2) co-activator binding surface to enhance co-activator binding, which results in a modest improvement in transcriptional efficacy. It binds to the PPARγ C-terminal ligand-binding domain (LBD) with a dissociation constant (K i) of 1.2 μM and demonstrates transcriptional efficacy with an effective concentration (EC 50) of 680 nM [1].